SAT0442 Risk factors for heart valve diseases in patients with antiphospholipid syndrome
K. Hiramoto(Keio University), Tsutomu Takeuchi(Keio University), Jun Kikuchi(Keio University), Yoko Kaneko(Keio University)
Cited by 0
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
|Annals of the Rheumatic Diseases|2007|413
NAK is an IκB kinase-activating kinase
|Nature|2000|374